Last updated: 2026-09-16 10:31:00. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Citius Oncology, Inc. (CTOR) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.86, with a market capitalisation of $99.41M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.49 to $2.25. This page covers its latest market performance, valuation, price trends and company information.
$99.41M | |
$0.95 | |
$6.19 | |
$0.49 | |
$0.94 | |
117.48K | |
80.94K | |
-- | |
$2.25 | |
$0.49 | |
-- | |
-- |
Citius Oncology, Inc. (CTOR) is trading at $0.97 in pre-market trading as of 2026-09-15 23:35:00, up 3.62% ($0.03) from the previous close of $0.94
Pre-market trading shows how investors are pricing CTOR before the regular session opens. The current pre-market price is above the previous close, indicating positive early trading sentiment.
Over the past seven days, Citius Oncology, Inc. (CTOR) moved from $0.86 to $0.86, representing a decline of 0.35% ($0.00).
The stock traded between $0.75 and $1.01 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 101.05 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 20.8%
CTOR is currently trading at $0.86, placing it 20.8% of the way from its 52-week low of $0.49 to its 52-week high of $2.25. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Citius Oncology, Inc. (CTOR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.